Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Compass Therapeutics
Biotech
Compass Therapeutics' stock heads south after bispecific OS miss
Compass shed half its stock price as investors digested its bispecific antibody’s failure to hit an overall survival endpoint in a phase 2/3 study.
James Waldron
Apr 27, 2026 10:55am
Trump orders FDA to fast-track reviews of psychedelic drugs
Apr 20, 2026 5:30am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
Compass inks Trigr takeover to land clinical-phase bispecific
May 14, 2021 8:35am
Compass aims at $50M IPO to push lead antibody through clinic
Oct 20, 2020 9:50am
Compass' immuno-oncology prospect clears solid tumors in mice
Apr 3, 2020 8:50am
